Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Gains from Investment Securities (2021 - 2024)

Historic Gains from Investment Securities for Coeptis Therapeutics Holdings (COEPW) over the last 3 years, with Q4 2024 value amounting to $539660.0.

  • Coeptis Therapeutics Holdings' Gains from Investment Securities changed N/A to $539660.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $539660.0, marking a year-over-year change of. This contributed to the annual value of $539660.0 for FY2024, which is N/A changed from last year.
  • Per Coeptis Therapeutics Holdings' latest filing, its Gains from Investment Securities stood at $539660.0 for Q4 2024.
  • Coeptis Therapeutics Holdings' 5-year Gains from Investment Securities high stood at $16.8 million for Q4 2021, and its period low was -$14.2 million during Q1 2021.
  • In the last 3 years, Coeptis Therapeutics Holdings' Gains from Investment Securities had a median value of -$150000.0 in 2022 and averaged -$29930.9.
  • Examining YoY changes over the last 5 years, Coeptis Therapeutics Holdings' Gains from Investment Securities showed a top increase of 9649.12% in 2022 and a maximum decrease of 13631.37% in 2022.
  • Coeptis Therapeutics Holdings' Gains from Investment Securities (Quarter) stood at $16.8 million in 2021, then plummeted by 100.89% to -$150000.0 in 2022, then surged by 459.77% to $539660.0 in 2024.
  • Its Gains from Investment Securities stands at $539660.0 for Q4 2024, versus -$150000.0 for Q3 2022 and -$599176.0 for Q2 2022.